Dalbavancin (DALVANCE) Order Form

SOMC Cancer Center & Infusion Ph: (740) 356-7490

Fx: (740) 356-7488

| PATIENT & PRESCRIBER INFORMATION | | | | | | |
|---|----------------|-----------|----------|------------------|----------------|----------------------------------|
| Patient Name: | | | DOB: | Phone: (| Н) | (C) |
| Patient Address: | | | | | | |
| Ht.: Wt.: □ lbs. □kg. Allergies: | | | | | | |
| Prescriber Name/Title: Address: | | | | | | |
| Phone: | Fax: | | P | rescriber NPI/ # | # : | |
| REQUIRED: Indication, most recent H&P and medication list is required unless the patient is established with SOMC. Supporting clinical notes should include rationale for indication; any past tried and/or failed therapies, intolerances, outcomes, or contraindications to conventional therapy-including why oral antibiotics are not being used if patient has a functioning gut. **Required for Restricted antibiotic.** Antimicrobial Stewardship Program (ASP) review/approval Current Micro Data (culture/sensitivity): Lab Results: Creatininemg/dL Date obtained | | | | | | |
| DIAGNOSIS, CLINICAL INFORMATION & PRESCRIPTION | | | | | | |
| □ May substitute mandated or preferred biosimilar as necessary. □ In the event of an adverse reaction, line maintenance/flushes, or O2 are required, the SOMC AIC established protocols will be utilized. □ D5W 250 ml primary at KVO during infusion (do not use normal saline), and flush line during observation period. ■ AND | | | | | | |
| Diagnosis Description: | | | | | | |
| Dose | | | | | | |
| Dalbavancin (DALVANCE) in 100-250 ml of 5% Dextrose in water (DSW) IV to infuse over 30 minutes. Estimated Creatinine Clearance* ☐ Single Dose Regimen ☐ Two-Dose Regimen | | | | | | |
| | | | | | | |
| ≥ 30 mL/min OR on regular hemodialysis | | | 1,500 mg | | 1,000 mg folio | owed one week later by 500 mg |
| < 30 mL/min and not on regular hemodialysis | | | 1,125 mg | | 750 mg follo | wed one week later by 375 mg |
| ☐Other dosing | | | | | | |
| Start date: Stop date: | | | | | | |
| Weekly Lab Orders | | | | | | |
| ☐ CBC w/diff | \square CRP | | | | | |
| ☐ Creatinine | \square ESR | | | | | |
| □ ВМР | \square None | | | | | |
| □ СМР | | | | | | |
| □ Other | | | | | | |
| | | i | _ | - | | |
| | | PROVIDER: | DATE: | TIME: | SIGNATURE: | |



Created: 06/21/23 P & T Comm.

Reviewed & Approved 06/21/23

Next Review Date 06/21/25

Version V06212025.0